Atazanavir: improving the HIV protease inhibitor class

Area of Science:

• Antiviral therapy
• HIV/AIDS research
• Pharmacology

Background:

• Protease inhibitors are crucial for HIV treatment but face challenges like poor pharmacokinetics, cross-resistance, and metabolic toxicities.
• Existing protease inhibitors often require multiple daily doses and can cause significant lipid and glycemic disturbances.

Purpose of the Study:

• To evaluate the efficacy, safety, and resistance profile of atazanavir, a novel protease inhibitor for HIV therapy.
• To compare atazanavir's clinical performance against established HIV medications.

Main Methods:

• Analysis of resistance patterns in clinical isolates exposed to atazanavir.
• Clinical trials comparing atazanavir to nelfinavir and efavirenz in treatment-naive patients.
• Preliminary studies assessing ritonavir-boosted atazanavir in patients with prior protease inhibitor treatment failure.

Main Results:

• Atazanavir exhibits a unique resistance profile, selecting for the I50L mutation which enhances susceptibility to other protease inhibitors.
• Clinical trials demonstrated comparable efficacy to nelfinavir and efavirenz in treatment-naive individuals.
• Ritonavir-boosted atazanavir showed effectiveness in patients with treatment-experienced HIV.

Conclusions:

• Atazanavir presents an improved option over current protease inhibitors, with advantages in dosing and metabolic safety.
• Its distinct resistance profile and clinical efficacy suggest utility in both initial and subsequent HIV treatment regimens.
• While reversible bilirubin elevations can occur, they are not linked to hepatic injury, indicating a favorable safety profile.